Bovilis BTV8

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

cjepivo protiv virusa bolesti plavog jezika, serotip 8 (inaktiviran)

Available from:

Intervet International BV

ATC code:

QI04AA02

INN (International Name):

bluetongue virus serotype 8

Therapeutic group:

Sheep; Cattle

Therapeutic area:

Инактивированные virusnih cjepiva, virus блютанга, ovce

Therapeutic indications:

Cattle To stimulate active immunity in sheep from 6 weeks of age against bluetongue virus serotype 8 to reduce viraemia Sheep To stimulate active immunity in sheep from 1 month of age against bluetongue virus serotype 8 to prevent viraemia,.

Product summary:

Revision: 4

Authorization status:

povučen

Authorization date:

2010-09-06

Patient Information leaflet

                                16
B. UPUTA O VMP
Lijek koji više nije odobren
17
UPUTA O VMP
BOVILIS BTV8 SUSPENZIJA ZA INJEKCIJE ZA GOVEDA I OVCE
1.
NAZIV I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE U PROMET I
NOSITELJA ODOBRENJA ZA PROIZVODNJU ODGOVORNOG ZA PUŠTANJE
PROIZVODNE SERIJE, AKO JE RAZLIČITO
Intervet International BV
Wim de Körverstraat 35,
5831 AN Boxmeer
NIZOZEMSKA
2.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
Bovilis BTV8 suspenzija za injekcije za goveda i ovce
3.
NAVOĐENJE DJELATNE(IH) TVARI I DRUGIH SASTOJAKA
Jedna doza (1 ml) sadržava:
Djelatni sastojak: virus bolesti plavog jezika serotip 8: 500
antigenske jedinice *
(* izaziva odgovor virus neutralizirajućih antitijela u pilića od
≥ 5,0 log2)
Adjuvansi: aluminij hidroksid, saponin.
Opalescentno ružičasta s resuspendiranim talogom.
4.
INDIKACIJE
Ovca
Za poticanje aktivnog imuniteta u ovaca od 1 mjeseca starosti protiv
virusa plavog jezika serotipa 8
kako bi se spriječila viremija*.
*(ciklička vrijednost (Ct) > 30 s provjerenom rRT-PCR metodom, što
ukazuje na odsutnost zaraznog virusa
)
Goveda
Za poticanje aktivnog imuniteta u goveda od 6 tjedana starosti protiv
virusa plavog jezika serotipa 8
kako bi se smanjila viremija*.
*(za detalje vidi odjeljak 12)
Početak imuniteta:
3 tjedna nakon cijepljenja.
Trajanje imunosti:
6 mjeseci.
5.
KONTRAINDIKACIJE
Nema.
6.
NUSPOJAVE
U vrlo rijetkim slučajevima cijepljenje može dovesti do blagog
porasta temperature (obično ne više od
0,5 °C, u pojedinim slučajevima do oko 2 °C) tri dana nakon
cijepljenja i privremenih otekline na
mjestu uboda. U ovaca, te otekline obično traju do tri tjedna, dok u
goveda male opipljive otekline
mogu biti prisutne i do šest tjedana nakon cijepljenja, u oko jedne
trećine cijepljenih životinja. Nakon
primjene dvostruke doze u goveda i ovaca nema drugih zabilježenih
reakcija. Međutim, porast
Lijek koji više nije odobren
18
temperature može biti 0.5 °C viši i otekline mogu biti izraženije
i opipljivije duži period. U ovaca,
otekline još uvijek mogu biti opipljive i nakon šest tj
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
DODATAK I
SAŽETAK OPISA SVOJSTAVA
Lijek koji više nije odobren
2
1.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
Bovilis BTV8 suspenzija za injekcije za goveda i ovce
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Jedna doza (1 ml) sadrži:
DJELATNA TVAR
:
Virusa bolesti plavog jezika serotip 8 (prije inaktivacije): 500 *
antigenih jedinica.
(* Izaziva odgovor virus neutralizacijskih antitijela u pilića od ≥
5,0 log2)
ADJUVANSI
Aluminij hidroksid (kao 100%)
16,7 mg
Saponina
0,31 mg
Za potpuni popis pomoćnih tvari vidi 6.1.
3.
FARMACEUTSKI OBLIK
Suspenzija za injekciju.
Opalescentno ružičasta s resuspendiranim talogom.
4.
KLINIČKE POJEDINOSTI
4.1
CILJNE VRSTE ŽIVOTINJA
Goveda i ovce.
4.2
INDIKACIJE ZA PRIMJENU, NAVESTI CILJNE VRSTE ŽIVOTINJA
Ovca
Za poticanje aktivnog imuniteta ovaca od 1 mjeseca starosti protiv
virusa plavog jezika serotipa 8
kako bi se spriječila viremija*.
* (ciklička vrijednost (Ct) > 30 provjerenom rRT-PCR metodom, ukazuje
na odsutnost infektivnog virusa
)
Goveda
Za poticanje aktivnog imuniteta goveda od 6 tjedana starosti protiv
virusa plavog jezika serotipa 8
kako bi se smanjila viremija *.
* (za detalje vidi odjeljak 4.4)
Početak imuniteta:
3 tjedna nakon cijepljenja.
Trajanje imunosti:
6 mjeseci
4.3
KONTRAINDIKACIJE
Nema.
Lijek koji više nije odobren
3
4.4
POSEBNA UPOZORENJA
Ovim cjepivom se smanjuje, ali ne i sprječava viremija u goveda.
Opseg ovog smanjenja je prikazan
ispitivanjem epidemiološkog modeliranja te se vjerojatno smanjuje
prijenos virusa u mjeri koja može
ograničiti širenje epidemije u cijepljene populacije.
Ovo cjepivo je testirano na neškodljivost u ovaca i goveda. Ako se
koristi kod drugih vrsta domaćih i
divljih preživača, kod kojih postoji rizik od infekcije, primjenu
cjepiva u tih vrsta treba provoditi
pažljivo. a Poželjno je testirati cjepivo na malom broju životinja
prije masovnog cijepljenja.
Djelotvornost u drugih vrsta može se razlikovati od onoga u ovaca i
goveda.
Nema podataka o korištenju cjepiva u seropozitivnih životinja,
uključujući i o
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 27-07-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 27-07-2022
Public Assessment Report Public Assessment Report Bulgarian 27-07-2022
Patient Information leaflet Patient Information leaflet Spanish 27-07-2022
Public Assessment Report Public Assessment Report Spanish 27-07-2022
Patient Information leaflet Patient Information leaflet Czech 27-07-2022
Public Assessment Report Public Assessment Report Czech 27-07-2022
Patient Information leaflet Patient Information leaflet Danish 27-07-2022
Public Assessment Report Public Assessment Report Danish 27-07-2022
Patient Information leaflet Patient Information leaflet German 27-07-2022
Public Assessment Report Public Assessment Report German 27-07-2022
Patient Information leaflet Patient Information leaflet Estonian 27-07-2022
Public Assessment Report Public Assessment Report Estonian 27-07-2022
Patient Information leaflet Patient Information leaflet Greek 27-07-2022
Public Assessment Report Public Assessment Report Greek 27-07-2022
Patient Information leaflet Patient Information leaflet English 27-07-2022
Public Assessment Report Public Assessment Report English 27-07-2022
Patient Information leaflet Patient Information leaflet French 27-07-2022
Public Assessment Report Public Assessment Report French 27-07-2022
Patient Information leaflet Patient Information leaflet Italian 27-07-2022
Public Assessment Report Public Assessment Report Italian 27-07-2022
Patient Information leaflet Patient Information leaflet Latvian 27-07-2022
Public Assessment Report Public Assessment Report Latvian 27-07-2022
Patient Information leaflet Patient Information leaflet Lithuanian 27-07-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 27-07-2022
Public Assessment Report Public Assessment Report Lithuanian 27-07-2022
Patient Information leaflet Patient Information leaflet Hungarian 27-07-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 27-07-2022
Public Assessment Report Public Assessment Report Hungarian 27-07-2022
Patient Information leaflet Patient Information leaflet Maltese 27-07-2022
Public Assessment Report Public Assessment Report Maltese 27-07-2022
Patient Information leaflet Patient Information leaflet Dutch 27-07-2022
Public Assessment Report Public Assessment Report Dutch 27-07-2022
Patient Information leaflet Patient Information leaflet Polish 27-07-2022
Public Assessment Report Public Assessment Report Polish 27-07-2022
Patient Information leaflet Patient Information leaflet Portuguese 27-07-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 27-07-2022
Public Assessment Report Public Assessment Report Portuguese 27-07-2022
Patient Information leaflet Patient Information leaflet Romanian 27-07-2022
Public Assessment Report Public Assessment Report Romanian 27-07-2022
Patient Information leaflet Patient Information leaflet Slovak 27-07-2022
Public Assessment Report Public Assessment Report Slovak 27-07-2022
Patient Information leaflet Patient Information leaflet Slovenian 27-07-2022
Summary of Product characteristics Summary of Product characteristics Slovenian 27-07-2022
Public Assessment Report Public Assessment Report Slovenian 27-07-2022
Patient Information leaflet Patient Information leaflet Finnish 27-07-2022
Public Assessment Report Public Assessment Report Finnish 27-07-2022
Patient Information leaflet Patient Information leaflet Swedish 27-07-2022
Public Assessment Report Public Assessment Report Swedish 27-07-2022
Patient Information leaflet Patient Information leaflet Norwegian 27-07-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 27-07-2022
Patient Information leaflet Patient Information leaflet Icelandic 27-07-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 27-07-2022

View documents history